Actively Recruiting
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Led by Jemincare · Updated on 2025-12-01
102
Participants Needed
1
Research Sites
162 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.
CONDITIONS
Official Title
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR), histologically or cytologically documented advanced solid tumor.
- Have at least one measurable lesion per RECIST v1.1.
- Have a life expectancy of 63 12 weeks.
- Have adequate organ function.
You will not qualify if you...
- Toxicities from prior anti-tumor therapy have not recovered to Grade 1 or below per CTCAE v5.0.
- History of prior malignancy in the past 3 years, except for curatively treated malignancies.
- Have dysphagia, impaired gastrointestinal function, or gastrointestinal disease that may significantly affect absorption of the study drug.
- Have severe chronic or active infection.
- Have a history of severe cardiovascular disease.
- Are pregnant or breastfeeding.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, China, 100142
Actively Recruiting
Research Team
L
Lu Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here